Stoke Therapeutics (STOK) Expected to Announce Quarterly Earnings on Monday

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) is expected to post its Q1 2025 quarterly earnings results before the market opens on Monday, May 5th. Analysts expect the company to announce earnings of ($0.42) per share and revenue of $27.37 million for the quarter.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.56) by $0.38. The company had revenue of $22.61 million during the quarter, compared to the consensus estimate of $4.20 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. On average, analysts expect Stoke Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Stoke Therapeutics Stock Down 2.4 %

Shares of Stoke Therapeutics stock traded down $0.24 on Friday, hitting $9.63. 640,908 shares of the company were exchanged, compared to its average volume of 710,291. The company has a 50-day moving average price of $7.90 and a 200 day moving average price of $10.18. The stock has a market capitalization of $525.77 million, a price-to-earnings ratio of -4.59 and a beta of 1.20. Stoke Therapeutics has a 1-year low of $5.35 and a 1-year high of $17.58.

Insiders Place Their Bets

In other news, insider Barry Ticho sold 3,884 shares of Stoke Therapeutics stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $33,674.28. Following the completion of the sale, the insider now directly owns 63,962 shares of the company's stock, valued at approximately $554,550.54. The trade was a 5.72 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Edward M. Md Kaye sold 10,382 shares of the stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $90,011.94. Following the transaction, the director now directly owns 148,253 shares in the company, valued at approximately $1,285,353.51. The trade was a 6.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 16,532 shares of company stock valued at $143,332 over the last 90 days. 11.30% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Needham & Company LLC restated a "buy" rating and issued a $22.00 target price on shares of Stoke Therapeutics in a report on Wednesday, April 9th. HC Wainwright restated a "buy" rating and set a $47.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Finally, Chardan Capital reiterated a "buy" rating and issued a $24.00 target price on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Stoke Therapeutics has a consensus rating of "Buy" and an average target price of $24.67.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.